Company intelligence / Profile preview

NxThera

Maple Grove, Minnesota, United States

Ownership: Private
Employees: ~39
Development stage: Other

Overview

The Rezūm system received FDA clearance in 2015[2] and has treated more than 20,000 patients[2]. Clinical studies demonstrated a 51% reduction in BPH symptoms at 24 months post-treatment with maintained 50% reduction at three years post-treatment[2]. Over a three-year period, patients treated with Rezūm had clinical progression rates five times lower than patients on daily long-term medications[2]. The system preserves sexual function compared to traditional surgical approaches[2].

Therapeutic areas: OncologyMen's Health
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on NxThera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NxThera.

Explore the full profile